Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal cell carcinoma

R J Motzer1, P Russo, D M Nanus

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Current Problems in Cancer
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.

Critical reviews in oncology/hematology·2015
Same author

Orthotopic model of renal cell carcinoma.

Methods in molecular medicine·2011
Same author

Reversal of the low-affinity neurotrophin receptor stromal-epithelial expression pattern between benign and malignant human prostate.

Urologic oncology·2011
Same author

Modulation of 11beta-hydroxysteroid dehydrogenase expression by bombesin: a possible mechanism for glucocorticoid resistance in androgen independent prostate cancer.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2008
Same author

Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.

Prostate cancer and prostatic diseases·2007
Same author

Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.

Cancer gene therapy·2007
Same journal

Clinical impact of a single time-point protocol paired FDG-PET and radioactive iodine scan for comprehensive disease assessment in differentiated thyroid cancer.

Current problems in cancer·2026
Same journal

Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database.

Current problems in cancer·2026
Same journal

Too late to fall: Time to PSA nadir and early oncologic failure after cryotherapy and high-intensity focused ultrasound for localized prostate cancer.

Current problems in cancer·2026
Same journal

Artificial intelligence, omics, and biomarkers: Redefining lung cancer early detection.

Current problems in cancer·2026
Same journal

Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.

Current problems in cancer·2026
Same journal

Advancements and perspectives of neoadjuvant immunotherapy in resectable non-small cell lung cancer.

Current problems in cancer·2026
See all related articles

Renal cell carcinoma (RCC) often presents with advanced disease and is resistant to traditional treatments. Improved diagnostics detect kidney cancer earlier, enhancing survival through surgical intervention for localized tumors.

Area of Science:

  • Oncology
  • Urology

Background:

  • Renal cell carcinoma (RCC) presents diagnostic challenges due to lack of early signs, leading to metastatic disease at diagnosis.
  • RCC incidence has risen, particularly in men over 40, with a median age in the mid-sixties.
  • Despite increased incidence, 5-year survival has improved, likely due to enhanced diagnostic capabilities.

Purpose of the Study:

  • To review the characteristics, diagnosis, and treatment of renal cell carcinoma.
  • To highlight the role of surgical management in localized RCC.
  • To discuss the challenges and research priorities in treating metastatic RCC.

Main Methods:

  • Review of diagnostic advancements in kidney cancer detection.
  • Analysis of surgical techniques for localized and recurrent RCC.

Related Experiment Videos

  • Evaluation of systemic therapies for metastatic RCC.

    • Main Results:

    • Advanced imaging techniques detect kidney tumors earlier, improving surgical cure rates.
    • Radical nephrectomy is the primary surgical treatment, with modifications like partial nephrectomy.
    • Metastatic RCC shows resistance to systemic therapies, with limited durable responses to immunotherapy.

    Conclusions:

    • Early detection through improved diagnostics is crucial for curative surgical treatment of localized RCC.
    • Surgical resection offers long-term survival in selected recurrent or metastatic cases.
    • Developing novel systemic agents for metastatic RCC remains a high priority due to treatment resistance.